COHANCE.NS Profit & Loss
Cohance Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:43
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹1,340.33 Cr. | ₹1,051.35 Cr. | ₹1,197.58 Cr. | ₹2,268.55 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹46.36 Cr. | ₹61.91 Cr. | ₹58.56 Cr. | ₹34.09 Cr. | OtherIncome |
| Total Income | ₹1,386.69 Cr. | ₹1,113.26 Cr. | ₹1,256.14 Cr. | ₹2,302.64 Cr. | Income |
| Cost of Materials Consumed | ₹430.08 Cr. | ₹265.88 Cr. | ₹222.66 Cr. | ₹705.39 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-20.94 Cr. | ₹49.16 Cr. | ₹82.63 Cr. | ₹-42.76 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹110.51 Cr. | ₹135.92 Cr. | ₹249.56 Cr. | ₹507.71 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹5.44 Cr. | ₹7.45 Cr. | ₹12.35 Cr. | ₹37.24 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹47.73 Cr. | ₹54.60 Cr. | ₹77.49 Cr. | ₹187.33 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹254.15 Cr. | ₹194.59 Cr. | ₹267.53 Cr. | ₹671.22 Cr. | OtherExpenses |
| Total Expenses | ₹826.96 Cr. | ₹707.59 Cr. | ₹912.22 Cr. | ₹2,066.13 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹559.73 Cr. | ₹405.67 Cr. | ₹343.92 Cr. | ₹236.51 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹-29.47 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹559.73 Cr. | ₹405.67 Cr. | ₹343.92 Cr. | ₹207.04 Cr. | ProfitBeforeTax |
| Tax Expense | ₹148.44 Cr. | ₹105.39 Cr. | ₹79.15 Cr. | ₹56.92 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹411.29 Cr. | ₹300.28 Cr. | ₹264.77 Cr. | ₹150.12 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | N/A | ₹0.00 Cr. | ₹267.87 Cr. | ₹179.23 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹16.16 | ₹11.80 | ₹10.52 | ₹4.69 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹16.16 | ₹11.80 | ₹10.45 | ₹4.68 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from COHANCE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).